TransMedics (TMDX) CCO Giovanni Cecere Receives Award

What Happened
Giovanni Cecere, Chief Commercial Officer of TransMedics Group, received equity awards on February 18, 2026: 11,082 restricted stock units (RSUs) and a derivative grant covering 16,734 shares (stock option). Both grants are reported at $0.00 per share (no purchase price); the RSUs represent a contingent right to one share each and the derivative is an option subject to vesting.

Key Details

• Transaction date: 2026-02-18; Form 4 filed 2026-02-20 (timely filing).
• Grants: 11,082 RSUs (F1) and a 16,734-share option/derivative (A). Reported price: $0.00.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote F1: Each RSU represents a contingent right to receive one share.
• Footnote F2: The option vests 25% on Feb 18, 2027, then the remainder in equal monthly installments over the following three years, subject to continued service.
• Transaction type: Award/grant (compensation), not an open-market buy or sell.

Context
RSUs convert to actual shares only as they vest; similarly, the option must vest per the schedule before it can be exercised. Awards like these are common executive compensation and do not by themselves indicate buying or selling sentiment.